Хроническая обструктивная болезнь легких и коморбидные сердечно-сосудистые заболевания: взгляд с позиций рекомендаций

2. Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis 2015; 10: 95–109. DOI: 10.2147/COPD.S54473
3. Chatila WM, Thomashow BM, Minai OA et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac So 2008; 5 (4): 549–55.
4. MacNee W. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive disease. Ann Med 2013; 45 (3): 291–300.
5. Чазова И.Е., Чучалин А.Г., Зыков К.А. и др. Диагностика и лечение пациентов с артериальной гипертонией и хронической обструктивной болезнью легких (Рекомендации Российского медицинского общества по артериальной гипертонии и Российского респираторного общества). Системные гипертензии. 2013; 1: 5–34. / Chazova I.E., Chuchalin A.G., Zykov K.A. i dr. Diagnostika i lechenie patsientov s arterial'noi gipertoniei i khronicheskoi obstruktivnoi bolezn'iu legkikh (Rekomendatsii Rossiiskogo meditsinskogo obshchestva po arterial'noi gipertonii i Rossiiskogo respiratornogo obshchestva). Systemic Hypertension. 2013; 10 (1): 5–34. [in Russian]
6. Farsang С, Kiss I, Tykarski A, Narkiewicz K. Treatment of Hypertension in Patients With Chronic Obstructive Pulmonary Disease (COPD) Update on Hypertension Management in COPD. Scientific Newsletter. 2016, 17, nr. 62. http: //www.eshonline.org/esh-content/uploads/2016/06/Treatment-of-Hypertension-in-Patients-With-Chronic-Obs...
7. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166 (3): 333–9.
8. Kim S-H, Park J-H, Lee J-K et al. Chronic obstructive pulmonary disease is independently associated with hypertension in men: A survey design analysis using nationwide survey data. Medicine. 2017; 96 (19): e6826. DOI: 10.1097/MD.0000000000006826
9. Мухарлямов Н.М., Саттбеков Ж.С., Сучков В.В. Системная артериальная гипертензия у больных хроническими неспецифическими заболеваниями легких. Кардиология. 1974; 34 (12): 55–61. / Mukharliamov N.M., Sattbekov Zh.S., Suchkov V.V. Sistemnaia arterial'naia gipertenziia u bol'nykh khronicheskimi nespetsificheskimi zabolevaniiami legkikh. Kardiologiia. 1974; 34 (12): 55–61. [in Russian]
10. Задионченко В.С., Адашева Т.В. Шилова Е.В. и др. Клинико-функциональные особенности артериальной гипертонии у больных хроническими обструктивными болезнями легких. РМЖ. 2003; 9: 535. / Zadionchenko V.S., Adasheva T.V. Shilova E.V. i dr. Kliniko-funktsional'nye osobennosti arterial'noi gipertonii u bol'nykh khronicheskimi obstruktivnymi bolezniami legkikh. RMZh. 2003; 9: 535. [in Russian]
11. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357.
12. Напалков Д.А., Панферов А.С. Особенности течения сердечно-сосудистых заболеваний и принципы выбора рациональной антигипертензивной терапии у больных хронической обструктивной болезнью легких. Системные гипертензии. 2013; 3: 77–9. / Napalkov D.A., Panferov A.S. Osobennosti techeniia serdechno-sosudistykh zabolevanii i printsipy vybora ratsional'noi antigipertenzivnoi terapii u bol'nykh khronicheskoi obstruktivnoi bolezn'iu legkikh. Systemic Hypertension. 2013; 10 (3): 77–9. [in Russian]
13. Melot C, Hallemans R, Naeije R et al. Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984; 130 (4): 612–6.
14. Dicpinigaitis PV, Thomas SA, Sherman MB et al. Losartan-induced bronchospasm. J Allergy Clin Immunol 1996; 98 (6 Pt 1): 1128–30.
15. Salpeter S, Ormiston T, Salpeter E. Cardioselective betablocker use in patients with reactive airway disease: a metaanalysis. Ann Intern Med 2002; 137: 715–25.
16. Kazani S, Israel E. Treatment with beta blockers in people with COPD. BMJ 2011; 342: d2655. DOI: 10.1136/bmj.d2655
17. Ponikowski P, Voors AA, Anker SD et al. ESC Scientific Document Group. Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности 2016. Рос. кардиологический журн. 2017; 1 (141): 7–81. / Ponikowski P, Voors AA, Anker SD et al. ESC Scientific Document Group. Rekomendatsii ESC po diagnostike i lecheniiu ostroi i khronicheskoi serdechnoi nedostatochnosti 2016. Ros. kardiologicheskii zhurn. 2017; 1 (141): 7–81. [in Russian]
18. Мареев В.Ю., Фомин И.В., Агеев Ф.Т. и др. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Общество специалистов по сердечной недостаточности. Российское кардиологическое общество. М., 2016. / Mareev V.Iu., Fomin I.V., Ageev F.T. i dr. Klinicheskie rekomendatsii. Khronicheskaia serdechnaia nedostatochnost' (KhSN). Obshchestvo spetsialistov po serdechnoi nedostatochnosti. Rossiiskoe kardiologicheskoe obshchestvo. M., 2016. [in Russian]
19. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Утверждены на Конгрессе ОССН 7 декабря 2012 г., на Правлении ОССН 31 марта 2013 и Конгрессе РКО 25 сентября 2013 г. Сердечная недостаточность. 2013; 14 (7): 379–472. / Mareev V.Iu., Ageev F.T., Arutiunov G.P. i dr. Natsional'nye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (chetvertyi peresmotr). Utverzhdeny na Kongresse OSSN 7 dekabria 2012 g., na Pravlenii OSSN 31 marta 2013 i Kongresse RKO 25 sentiabria 2013 g. Serdechnaia nedostatochnost'. 2013; 14 (7): 379–472. [in Russian]
20. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Committee for Practice Guidelines. Рекомендации Европейского общества кардиологов (EOK) по диагностике и лечению острой и хронической сердечной недостаточности 2012 г. Рос. кардиологический журн. 2012; 4 (102), Прил. 3. / McMurray JJ, Adamopoulos S, Anker SD et al. ESC Committee for Practice Guidelines. Rekomendatsii Evropeiskogo obshchestva kardiologov (EOK) po diagnostike i lecheniiu ostroi i khronicheskoi serdechnoi nedostatochnosti 2012 g. Ros. kardiologicheskii zhurn. 2012; 4 (102), Pril. 3. [in Russian]
21. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. Am J Coll Cardiol 2007; 49 (2): 171–80.
22. Garcia-Rodriguez LA, Wallander MA, Martin-Merino E, Johansson S. Heart failure, myocardial infarction, lung cancer and death in COPD patients: a UK primary care study. Respir Med 2010; 104 (11): 1691–9.
23. Franssen FM, Rochester CL. Comorbidities in patients with COPD and pulmonary rehabilitation: do they matter? Eur Respir Rev 2014; 23 (131): 131–41.
24. Rutten FH, Cramer MJ, Grobbee DE et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005; 26 (18): 1887–94.
25. Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis 2014; 9: 871–88. DOI: 10.2147/COPD.S49621
26. Halpin DM, Decramer M, Celli B et al. Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT(R) trial. Lung 2011; 189 (4): 261–8.
27. Miller J, Edwards LD, Agustí A et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013; 107 (9): 1376–84. DOI: 10.1016/j.rmed.2013.05.001
28. Чучалин А.Г. Хроническая обструктивная болезнь легких и сопутствующие заболевания. Часть I. ХОБЛ и поражения сердечно-сосудистой системы. РМЖ. 2008; 10: 58–65. / Chuchalin A.G. Khronicheskaia obstruktivnaia bolezn' legkikh i soputstvuiushchie zabolevaniia. Chast' I. KhOBL i porazheniia serdechno-sosudistoi sistemy. RMZh. 2008; 10: 58–65.  [in Russian]
29. Kleiger RE, Senior RM. Longterm electrocardiographic monitoring of ambulatory patients with chronic airway obstruction. Chest 1974; 65 (5): 483–7.
30. Задионченко В.С. и др. Нарушения ритма сердца у больных хроническими обструктивными болезнями легких. Пульмонология. 2003; 6: 88–99. / Zadionchenko V.S. i dr. Narusheniia ritma serdtsa u bol'nykh khronicheskimi obstruktivnymi bolezniami legkikh. Pul'monologiia. 2003; 6: 88–99. [in Russian]
31. Fuso L, Incalzi RA, Pistelli R et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995; 98 (3): 272–7.
32. Ревишвили А.Ш., Рзаев Ф.Г., Горев М.В., Нардая Ш.Г. Клинические рекомендации «Фибрилляция предсердий». Рекомендации Всероссийского научного общества специалистов по клинической электрофизиологии, аритмологии и электрокардиостимуляции (ВНОА), Российского кардиологического общества (РКО) и Ассоциации сердечно‐сосудистых хирургов России (АССХ). 2017. / Revishvili A.Sh., Rzaev F.G., Gorev M.V., Nardaia Sh.G. Klinicheskie rekomendatsii «Fibrilliatsiia predserdii». Rekomendatsii Vserossiiskogo nauchnogo obshchestva spetsialistov po klinicheskoi elektrofiziologii, aritmologii i elektrokardiostimuliatsii (VNOA), Rossiiskogo kardiologicheskogo obshchestva (RKO) i Assotsiatsii serdechno‐sosudistykh khirurgov Rossii (ASSKh). 2017. [in Russian]
33. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 2016; 50 (5): e1–e88.
34. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY et al. Рекомендации по диагностике и лечению фибрилляции предсердий 2010. Рабочая группа Европейского общества кардиологов (ESC). Рациональная фармакотерапия в кардиологии. 2011 (Прил. к №1–2). / European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY et al. Rekomendatsii po diagnostike i lecheniiu fibrilliatsii predserdii 2010. Rabochaia gruppa Evropeiskogo obshchestva kardiologov (ESC). Ratsional'naia farmakoterapiia v kardiologii. 2011 (Pril. k №1–2). [in Russian]
35. Сулимов В.А., Голицын С.П., Панченко Е.П. и др. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. М., 2012. / Sulimov V.A., Golitsyn S.P., Panchenko E.P. i dr. Diagnostika i lechenie fibrilliatsii predserdii. Rekomendatsii RKO, VNOA i ASSKh. M., 2012. [in Russian]
36. Curkendall SM, DeLuise C, Jones JK et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16 (1): 63–70.
37. Авдеев С.Н., Баймаканова Г.Е. Сердечно-сосудистые заболевания у больных ХОБЛ: проблема выбора лекарственных препаратов. Атмосфера. Пульмонология и аллергология. 2008; 2: 3–8. / Avdeev S.N., Baimakanova G.E. Serdechno-sosudistye zabolevaniia u bol'nykh KhOBL: problema vybora lekarstvennykh preparatov. Atmosfera. Pul'monologiia i allergologiia. 2008; 2: 3–8. [in Russian]
38. Hole DJ, Watt GC, Davey-Smith G et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ : Br Med J 1996; 313 (7059): 711–6.
39. Sin DD, Wu L, Anderson JA et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60 (12): 992–7.
40. McAllister DA, Maclay JD, Mills NL et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176 (12): 1208–14.
41. Eickhoff P, Valipour A, Kiss D et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178 (12): 1211–8.
42. Thomsen M, Dahl M, Lange P et al. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186 (10): 982–8.
43. Cote CG, Casanova C, Marín JM et al. Validation and comparison of reference equations for the 6-min walk distance test. Eur Respir J 2008; 31 (3): 571–8.
44. Divo M, Cote C, de Torres JP et al. BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186 (2): 155–61. DOI: 10.1164/rccm.201201-0034OC
45. Brekke PH, Omland T, Smith P, Soyseth V. Underdiagnosis of myocardial infarction in COPD: Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respir Med 2008; 102 (9): 1243–7.
46. Chang CL, Robinson SC, Mills GD et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011; 66 (9): 764–8. DOI: 10.1136/thx.2010.155333
47. Ibanez B, James S, Agewall S et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (2): 119–77. DOI: 10.1093/eurheartj/ehx393
48. Roffi M, Patrono C, Collet JP et al. Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016 ; 37 (3): 267–315. DOI: 10.1093/eurheartj/ehv320
49. Task Force Members, Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34 (38): 2949–3003. DOI: 10.1093/eurheartj/eht296

________________________________________________

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD 2017. http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf
2. Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis 2015; 10: 95–109. DOI: 10.2147/COPD.S54473
3. Chatila WM, Thomashow BM, Minai OA et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac So 2008; 5 (4): 549–55.
4. MacNee W. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive disease. Ann Med 2013; 45 (3): 291–300.
5. Chazova I.E., Chuchalin A.G., Zykov K.A. i dr. Diagnostika i lechenie patsientov s arterial'noi gipertoniei i khronicheskoi obstruktivnoi bolezn'iu legkikh (Rekomendatsii Rossiiskogo meditsinskogo obshchestva po arterial'noi gipertonii i Rossiiskogo respiratornogo obshchestva). Systemic Hypertension. 2013; 10 (1): 5–34. [in Russian]
6. Farsang С, Kiss I, Tykarski A, Narkiewicz K. Treatment of Hypertension in Patients With Chronic Obstructive Pulmonary Disease (COPD) Update on Hypertension Management in COPD. Scientific Newsletter. 2016, 17, nr. 62. http: //www.eshonline.org/esh-content/uploads/2016/06/Treatment-of-Hypertension-in-Patients-With-Chronic-Obs...
7. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166 (3): 333–9.
8. Kim S-H, Park J-H, Lee J-K et al. Chronic obstructive pulmonary disease is independently associated with hypertension in men: A survey design analysis using nationwide survey data. Medicine. 2017; 96 (19): e6826. DOI: 10.1097/MD.0000000000006826
9. Mukharliamov N.M., Sattbekov Zh.S., Suchkov V.V. Sistemnaia arterial'naia gipertenziia u bol'nykh khronicheskimi nespetsificheskimi zabolevaniiami legkikh. Kardiologiia. 1974; 34 (12): 55–61. [in Russian]
10. Zadionchenko V.S., Adasheva T.V. Shilova E.V. i dr. Kliniko-funktsional'nye osobennosti arterial'noi gipertonii u bol'nykh khronicheskimi obstruktivnymi bolezniami legkikh. RMZh. 2003; 9: 535. [in Russian]
11. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357.
12. Napalkov D.A., Panferov A.S. Osobennosti techeniia serdechno-sosudistykh zabolevanii i printsipy vybora ratsional'noi antigipertenzivnoi terapii u bol'nykh khronicheskoi obstruktivnoi bolezn'iu legkikh. Systemic Hypertension. 2013; 10 (3): 77–9. [in Russian]
13. Melot C, Hallemans R, Naeije R et al. Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984; 130 (4): 612–6.
14. Dicpinigaitis PV, Thomas SA, Sherman MB et al. Losartan-induced bronchospasm. J Allergy Clin Immunol 1996; 98 (6 Pt 1): 1128–30.
15. Salpeter S, Ormiston T, Salpeter E. Cardioselective betablocker use in patients with reactive airway disease: a metaanalysis. Ann Intern Med 2002; 137: 715–25.
16. Kazani S, Israel E. Treatment with beta blockers in people with COPD. BMJ 2011; 342: d2655. DOI: 10.1136/bmj.d2655
17. Ponikowski P, Voors AA, Anker SD et al. ESC Scientific Document Group. Rekomendatsii ESC po diagnostike i lecheniiu ostroi i khronicheskoi serdechnoi nedostatochnosti 2016. Ros. kardiologicheskii zhurn. 2017; 1 (141): 7–81. [in Russian]
18. Mareev V.Iu., Fomin I.V., Ageev F.T. i dr. Klinicheskie rekomendatsii. Khronicheskaia serdechnaia nedostatochnost' (KhSN). Obshchestvo spetsialistov po serdechnoi nedostatochnosti. Rossiiskoe kardiologicheskoe obshchestvo. M., 2016. [in Russian]
19. Mareev V.Iu., Ageev F.T., Arutiunov G.P. i dr. Natsional'nye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (chetvertyi peresmotr). Utverzhdeny na Kongresse OSSN 7 dekabria 2012 g., na Pravlenii OSSN 31 marta 2013 i Kongresse RKO 25 sentiabria 2013 g. Serdechnaia nedostatochnost'. 2013; 14 (7): 379–472. [in Russian]
20. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Committee for Practice Guidelines. Rekomendatsii Evropeiskogo obshchestva kardiologov (EOK) po diagnostike i lecheniiu ostroi i khronicheskoi serdechnoi nedostatochnosti 2012 g. Ros. kardiologicheskii zhurn. 2012; 4 (102), Pril. 3. [in Russian]
21. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. Am J Coll Cardiol 2007; 49 (2): 171–80.
22. Garcia-Rodriguez LA, Wallander MA, Martin-Merino E, Johansson S. Heart failure, myocardial infarction, lung cancer and death in COPD patients: a UK primary care study. Respir Med 2010; 104 (11): 1691–9.
23. Franssen FM, Rochester CL. Comorbidities in patients with COPD and pulmonary rehabilitation: do they matter? Eur Respir Rev 2014; 23 (131): 131–41.
24. Rutten FH, Cramer MJ, Grobbee DE et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005; 26 (18): 1887–94.
25. Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis 2014; 9: 871–88. DOI: 10.2147/COPD.S49621
26. Halpin DM, Decramer M, Celli B et al. Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT(R) trial. Lung 2011; 189 (4): 261–8.
27. Miller J, Edwards LD, Agustí A et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013; 107 (9): 1376–84. DOI: 10.1016/j.rmed.2013.05.001
28. Chuchalin A.G. Khronicheskaia obstruktivnaia bolezn' legkikh i soputstvuiushchie zabolevaniia. Chast' I. KhOBL i porazheniia serdechno-sosudistoi sistemy. RMZh. 2008; 10: 58–65.  [in Russian]
29. Kleiger RE, Senior RM. Longterm electrocardiographic monitoring of ambulatory patients with chronic airway obstruction. Chest 1974; 65 (5): 483–7.
30. Zadionchenko V.S. i dr. Narusheniia ritma serdtsa u bol'nykh khronicheskimi obstruktivnymi bolezniami legkikh. Pul'monologiia. 2003; 6: 88–99. [in Russian]
31. Fuso L, Incalzi RA, Pistelli R et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995; 98 (3): 272–7.
32. Revishvili A.Sh., Rzaev F.G., Gorev M.V., Nardaia Sh.G. Klinicheskie rekomendatsii «Fibrilliatsiia predserdii». Rekomendatsii Vserossiiskogo nauchnogo obshchestva spetsialistov po klinicheskoi elektrofiziologii, aritmologii i elektrokardiostimuliatsii (VNOA), Rossiiskogo kardiologicheskogo obshchestva (RKO) i Assotsiatsii serdechno‐sosudistykh khirurgov Rossii (ASSKh). 2017. [in Russian]
33. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 2016; 50 (5): e1–e88.
34. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY et al. Rekomendatsii po diagnostike i lecheniiu fibrilliatsii predserdii 2010. Rabochaia gruppa Evropeiskogo obshchestva kardiologov (ESC). Ratsional'naia farmakoterapiia v kardiologii. 2011 (Pril. k №1–2). [in Russian]
35. Sulimov V.A., Golitsyn S.P., Panchenko E.P. i dr. Diagnostika i lechenie fibrilliatsii predserdii. Rekomendatsii RKO, VNOA i ASSKh. M., 2012. [in Russian]
36. Curkendall SM, DeLuise C, Jones JK et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16 (1): 63–70.
37. Avdeev S.N., Baimakanova G.E. Serdechno-sosudistye zabolevaniia u bol'nykh KhOBL: problema vybora lekarstvennykh preparatov. Atmosfera. Pul'monologiia i allergologiia. 2008; 2: 3–8. [in Russian]
38. Hole DJ, Watt GC, Davey-Smith G et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ : Br Med J 1996; 313 (7059): 711–6.
39. Sin DD, Wu L, Anderson JA et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60 (12): 992–7.
40. McAllister DA, Maclay JD, Mills NL et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176 (12): 1208–14.
41. Eickhoff P, Valipour A, Kiss D et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178 (12): 1211–8.
42. Thomsen M, Dahl M, Lange P et al. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186 (10): 982–8.
43. Cote CG, Casanova C, Marín JM et al. Validation and comparison of reference equations for the 6-min walk distance test. Eur Respir J 2008; 31 (3): 571–8.
44. Divo M, Cote C, de Torres JP et al. BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186 (2): 155–61. DOI: 10.1164/rccm.201201-0034OC
45. Brekke PH, Omland T, Smith P, Soyseth V. Underdiagnosis of myocardial infarction in COPD: Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respir Med 2008; 102 (9): 1243–7.
46. Chang CL, Robinson SC, Mills GD et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011; 66 (9): 764–8. DOI: 10.1136/thx.2010.155333
47. Ibanez B, James S, Agewall S et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (2): 119–77. DOI: 10.1093/eurheartj/ehx393
48. Roffi M, Patrono C, Collet JP et al. Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016 ; 37 (3): 267–315. DOI: 10.1093/eurheartj/ehv320
49. Task Force Members, Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34 (38): 2949–3003. DOI: 10.1093/eurheartj/eht296

О.Д.Остроумова*1,2, А.И.Кочетков1

1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва,  ул. Трубецкая, д. 8, стр. 2 
*ostroumova.olga@mail.ru

________________________________________________

2 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2